Initial experience of a MitraClip valve repair program in Spain

• Published in: Annals of translational medicine Vol. 8; no. 15; p. 957
• Main Authors: Henández-Vaquero, Daniel, Pascual, Isaac, Almendarez, Marcel, Adeba, Antonio, Alperi, Alberto, Lorca, Rebeca, Cubero-Gallego, Héctor, León, Víctor, Fernández Suárez, Félix E, Fernández Del Valle, David, Morís, César, Avanzas, Pablo
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.08.2020
• Subjects: Original on Structural Heart Disease: The Revolution; program; MitraClip; valve repair; Spain
• DOI: 10.21037/atm.2020.02.121
• ISSN: 2305-5839

The main objective of this study was to evaluate one-year clinical outcome of patients with symptomatic mitral regurgitation (MR) treated with transcatheter mitral valve repair (TMVR) according to the etiology of MR. Data from a single high-volume center of all consecutive cases with symptomatic MR undergoing TMVR where prospectively included and followed. Between October 2015 and October 2019, 81 consecutive patients underwent TMVR and were included in the investigation. The mean age was 75.73±7.81 years, 55 (67.9%) were male. The most frequent mechanism was functional MR (FMR) (59%). The mean EuroSCORE II was 5.7±4.94 [FMR 5.38±3.9, degenerative MR (DMR) 5.72±4.7 and mixed MR (MMR) 6.6±7.5; P=0.7776] and STS score mean was 5.21±3.31 (FMR 4.6±2.3, DMR 6.43±5.2 and MMR 5.7±3.2; P=0.126). Patients with FMR had higher rates of dilated (36 patients, 75.5%) and ischemic (15 patients, 31.3%) cardiomyopathy, as well as worse left ventricular ejection fraction (LVEF). Procedural success was achieved in 72 (88.9%) patients, with a similar distribution between groups. The median of follow-up was 16.3 months. The primary combined endpoint occurred in 19 (23.5%) cases. The number of the combined event regarding the different etiologies were 15 (31.2%) in FMR, 2 (11.8%) in DMR and 5 (31.3%) in MMR (P=0.276). Sixteen patients (20.0%) died during the first year of follow-up and 19 (23.5%) had unplanned heart failure (HF) hospitalization. Previous surgical revascularization (HR =4.94, P=0.004) and a redo TMVR (HR =11.3, P=0.006) predicted the main event. TMVR with the Mitraclip device is safe, with a low incidence of complications and a high rate of procedural success. One-year outcomes show reduction of all cause death and HF admissions. Moreover, most of the patients have sustained MR reduction and an improvement in the functional class at the end of follow-up.